Early data on patients treated in Cohort C of the ALLOHA™ Phase 1 heme trial expected in the second quarter of 2026 Initiation of Phase 3 study of TSC-101 (ALLOHA-2 ™) planned for the second quarter ...
Data from ALLOHA™ Phase 1 heme trial to be presented at the 67 th American Society of Hematology (ASH) Annual Meeting and Exposition Made the strategic decision to prioritize clinical development of ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest announcement is out from TScan ...
TScan Therapeutics Inc. (NASDAQ:TCRX), a biotechnology company focused on developing T-cell receptor-engineered T cell therapies, stands at a critical juncture as it approaches key milestones in its ...
(MENAFN- GlobeNewsWire - Nasdaq) Two-year relapse data from ALLOHATM Phase 1 heme trial to be presented by end of year Expects to dose first solid tumor patients with multiplex TCR-T in the third ...
TScan Therapeutics Inc. (NASDAQ:TCRX), a biotechnology company specializing in T-cell receptor (TCR) engineered T cell therapies, stands at a critical juncture in its development pipeline. With key ...
(MENAFN- GlobeNewsWire - Nasdaq) Updates from the PLEXI-TTM solid tumor and ALLOHATM heme Phase 1 clinical trials anticipated by end of year On-track to file IND application for TSC-102-A0301 (CD45; ...
WALTHAM, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell ...
TScan Therapeutics announces $30 million investment from Lynx1 Capital Management for pre-funded warrants, extending cash runway into early 2027. TScan Therapeutics, Inc. has announced a securities ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results